While our study exclusively focused on modeling the 90% of SMS cases that carry del(17)p11.2, future studies that model the remaining 10% of SMS cases with RAI1 heterozygous mutations will enable a full understanding of disease pathology. This evidence concerns the gene RAI1 and Smith-Magenis syndrome.